Anzeige
Erschienen in:
01.02.2020 | Original Article
Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis
Erschienen in: Journal of Endocrinological Investigation | Ausgabe 2/2020
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Autoimmune thyroid events (ATEs) are common side effects after alemtuzumab (ALZ) therapy in patients with multiple sclerosis (MS). Our purpose was to reach more robust evidence on prevalence and outcome of the spectrum of alemtuzumab-induced autoimmune thyroid events in patients with multiple sclerosis.
Methods
PubMed and Scopus were systematically searched through July 2019. Studies dealing with patients without personal history of thyroid dysfunctions and affected by MS treated with ALZ and reporting ATEs were selected. Data on prevalence and outcome of ATEs were extracted. A proportion of meta-analysis with random-effects model was performed.
Results
Considering the overall pooled number of 1362 MS patients treated with ALZ (seven included studies), a 33% prevalence of newly diagnosed ATEs was recorded. Among all ATEs, Graves’ disease (GD) was the most represented [63% of cases, 95% confidence interval (CI) 52–74%], followed by Hashimoto thyroiditis (15%, 95% CI 10–22%). Interestingly, GD showed a fluctuating course in 15% of cases (95% CI 8–25%). Of all GD, 12% (95% CI 2–42%) likely had spontaneous remission, 56% (95% CI 34–76%) required only antithyroid drugs, 22% (95% CI 13–32%) needed additional RAI, and 11% (95% CI 0.9–29%) underwent definitive surgery.
Conclusion
Among different categories of ATEs, Graves’ hyperthyroidism was the most common thyroid dysfunction, occurring in more than half of cases. Antithyroid drugs should represent the first-line treatment for ALZ-induced GD patients. However, alemtuzumab-induced GD could not be considered as having a more favourable outcome than conventional GD, given the substantial chance to encounter a fluctuating and unpredictable course.